TriSalus Life Sciences Inc. SEC Filings

TriSalus Life Sciences, Inc. (TLSI) reported equity awards to its Chief of Clinical Operations on a Form 4. The officer received 50,000 shares of common stock as a restricted stock unit (RSU) award on November 24, 2025, which will vest in four equal annual installments starting on that date, conditioned on continued employment at each vesting date.

The officer was also granted an employee stock option to buy 100,000 shares of common stock at an exercise price of $5.55 per share. One-fourth of the option shares vest on the one-year anniversary of the November 24, 2025 vesting commencement date, and the remaining shares vest monthly in equal installments over the following three years, also subject to continued employment. Following these grants, the reporting person beneficially owned 100,571 shares of common stock directly and 463,750 derivative securities in the form of options.

TriSalus Life Sciences (TLSI) reported new equity awards to its CEO and President, Mary Szela, in a Form 4 filing. She received 125,000 performance stock units (PSUs) on 02/13/2024 that vest upon achieving or exceeding $50 million of revenue over any 12‑month period ending on or before February 28, 2027. On 11/24/2025 she was granted 125,000 restricted stock units that vest in four equal annual installments starting November 24, 2025.

Also on 11/24/2025, she received 300,000 additional PSUs tied to achieving or exceeding $75 million of revenue over any 12‑month period ending on or before December 31, 2027, with 150,000 vesting upon achievement and 150,000 vesting one year later. She was further granted an option to buy 250,000 shares at $5.55 per share, expiring on 11/23/2035, vesting over four years. After these transactions, she beneficially owns 742,802 common shares and 1,578,182 derivative securities directly.

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Regulatory Officer on a Form 4. On November 24, 2025, the officer received 50,000 restricted stock units payable in common stock at a price of $0, with the award vesting in four equal annual installments starting November 24, 2025, subject to continued employment. The filing also discloses an employee stock option to purchase 100,000 shares of common stock at an exercise price of $5.55 per share, with one-fourth vesting on the one-year anniversary of November 24, 2025 and the remainder vesting monthly over three years, also conditioned on continued employment.

After these transactions, the officer beneficially owns 127,640 shares of common stock directly and 323,782 derivative securities, reflecting equity-based incentives tied to future service.

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its Chief Commercial Officer on a Form 4. On November 24, 2025, the officer received 60,000 shares of common stock in the form of restricted stock units at a price of $0, bringing direct beneficial ownership of common stock to 113,854 shares after the transaction.

The same day, the officer was also granted an employee stock option to purchase 120,000 shares of common stock at an exercise price of $5.55 per share, with 408,937 derivative securities beneficially owned following the transaction. The RSUs vest in four equal annual installments starting on November 24, 2025, and the option vests over four years, with one-fourth vesting on the first anniversary of the vesting commencement date and the remainder vesting monthly through November 23, 2035, in each case subject to continued employment.

TriSalus Life Sciences, Inc. (TLSI) reported an equity compensation grant to its chief financial officer in a Form 4 filing. On 11/24/2025, the officer received 65,000 shares of common stock as a restricted stock unit (RSU) award at a price of $0, increasing beneficial ownership of common stock to 265,000 shares held directly.

The filing also reports an employee stock option grant to buy 130,000 shares of common stock at an exercise price of $5.55 per share, expiring on 11/23/2035. The RSU award vests in four equal annual installments starting 11/24/2025, while one-fourth of the option vests on the one-year anniversary of 11/24/2025 and the remaining shares vest monthly over the following three years, in each case subject to continued employment. Following this option grant, the officer beneficially owns 668,899 derivative securities directly.

TriSalus Life Sciences, Inc. filed an S-3 shelf registration to offer up to $150,000,000 of securities, including common stock, preferred stock, debt securities, warrants, and units, which may be sold from time to time. Any specific terms and pricing will be set in a future prospectus supplement.

Net proceeds, if and when raised, are intended for general corporate purposes. The company’s Common Stock trades on Nasdaq as “TLSI,” with a closing price of $4.00 on November 10, 2025. Shares outstanding were 49,964,311 as of November 10, 2025; this is a baseline figure, not the amount being offered. TriSalus is an emerging growth company and a smaller reporting company, which allows scaled disclosure.

TriSalus Life Sciences (TLSI) reported Q3 2025 results. Revenue reached $11.566M, up from $7.349M a year ago, with gross profit of $9.660M. The company recorded a net loss of $10.811M and a net loss per share of $0.96. After preferred stock conversion-related charges, net loss attributable to common stockholders was $41.274M.

Cash and cash equivalents were $22.687M as of September 30, 2025. Total assets were $36.463M versus total liabilities of $63.188M, resulting in a stockholders’ deficit of $(26.725)M. Management disclosed substantial doubt about the company’s ability to continue as a going concern. Financing activity included drawing $10.0M under the OrbiMed facility in February, bringing long-term debt to $32.764M. Operating cash use improved year over year to $(15.528)M for the nine months, and year‑to‑date revenue rose to $31.946M from $21.170M.

TriSalus Life Sciences (TLSI) furnished a press release providing a business update and financial results for the quarter ended September 30, 2025.

The release is attached as Exhibit 99.1 and, along with the Inline XBRL cover file (Exhibit 104), is furnished and not deemed filed under Section 18, and is incorporated by reference only if specifically referenced.